The company
Castle Biosciences, Inc.
CSTL · Nasdaq
CSTL stood above a rising 150-day average in 20 of the last 52 weekly readings, including each of the last 3 weeks. It is 19.3% above that average now. Diagnostics & Labs: 48% of its 44 stocks in an uptrend (−2 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Just started moving
- Weeks in an uptrend
- 3 in a row
- Industry in uptrend
- 48% -2 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $32.1M
- Officials’ trades on record
- 3
- Institutions holding
- 168 (-4)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 20 of 52 weeks.
Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
3 disclosed lines: House 3, Senate 0, executive 0; 2 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Josh Gottheimer House: U.S. House ClerkNJ05 | soldjoint | $1k–$15k | 15 Mar 2022filed 17 Apr 2022 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39 | bought | $1k–$15k | 23 Dec 2020filed 11 Jan 2021 |
| Josh Gottheimer House: U.S. House ClerkNJ05 | bought | $1k–$15k | 21 Dec 2020filed 7 Jan 2021 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Tobin W. JuvenalChief Commercial Officer | sold | 3,288at $33.64 | 12 Oct 2026filed 14 Oct 2026 |
| Derek J. MaetzoldPres. & Chief Exec. Officer | sold | 8,580at $35.57 | 5 Oct 2026filed 7 Oct 2026 |
| Derek J. MaetzoldPres. & Chief Exec. Officer | sold | 3,198at $35.57 | 5 Oct 2026filed 7 Oct 2026 |
| Derek J. MaetzoldPres. & Chief Exec. Officer | sold | 2,718at $35.57 | 5 Oct 2026filed 7 Oct 2026 |
| Kristen M. OelschlagerChief Operating Officer | sold | 2,807at $35.75 | 1 Oct 2026filed 5 Oct 2026 |
| Kristen M. OelschlagerChief Operating Officer | sold | 1,346at $36.38 | 1 Oct 2026filed 5 Oct 2026 |
| Tobin W. JuvenalChief Commercial Officer | sold | 1,034at $34.20 | 30 Sep 2026filed 1 Oct 2026 |
| Tobin W. JuvenalChief Commercial Officer | sold | 5,543at $35.50 | 29 Sep 2026filed 1 Oct 2026 |
| Derek J. MaetzoldPres. & Chief Exec. Officer | sold | 8,580at $35.33 | 21 Sep 2026filed 23 Sep 2026 |
| Derek J. MaetzoldPres. & Chief Exec. Officer | sold | 3,198at $35.33 | 21 Sep 2026filed 23 Sep 2026 |
| Derek J. MaetzoldPres. & Chief Exec. Officer | sold | 2,718at $35.33 | 21 Sep 2026filed 23 Sep 2026 |
| Tobin W. JuvenalChief Commercial Officer | sold | 3,294at $35.14 | 15 Sep 2026filed 16 Sep 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.added · filed 7 Aug 2026 | 3,291,963$78.5M | +309,017+10.4% |
| RTW INVESTMENTS, LPadded · filed 14 Aug 2026 | 2,778,335$66.3M | +20,000+0.7% |
| PRINCIPAL FINANCIAL GROUP INCreduced · filed 4 Aug 2026 | 1,726,648$41.2M | -43,229−2.4% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,226,497$29.3M | +48,975+4.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026 | 840,785$20.1M | -20,986−2.4% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLCreduced · filed 14 Aug 2026 | 824,872$19.7M | -115,813−12.3% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 822,079$19.6M | +53,000+6.9% |
| Allianz Asset Management GmbHunchanged · filed 14 Aug 2026 | 811,324$19.9M | 00.0% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 795,912$19.0M | +67,812+9.3% |
| MACKENZIE FINANCIAL CORPadded · filed 13 Aug 2026 | 793,507$18.9M | +719,396+970.7% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.